Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Hsien-Yuan Lane, M.D.,Ph.D. is the Director and Professor of Department of Psychiatry and Institute of Clinical Medical Science at China Medical University Medical College, Taichung, Taiwan. He has been devoted to translational studies and clinical trials,especially those on several NMDA-enhancing agents for treatment of various mental disorders. His team is the first group to demonstrate the therapeutic efficacy of glycine transporter I inhibitor inpatients with schizophrenia, setting the tone of these lines of novel treatments. Dr Lane’s group is also the pioneer in clinical trials on glycine transporter I inhibitor for treatment of major depressive disorder.Moreover, Dr Lane’s group leads in clinical trials to show the efficacy of DAAO inhibitor (sodium benzoate in their trials) for treatment of schizophrenia and early-phase Alzheimer's disease.Finally, his group lately found that G72 (DAOA) protein level in plasma may be the first peripheral biomarker for schizophrenia.To sum up, Dr Lane’s group is the pioneer in translational studies on glycine transporter I inhibitor and DAAO inhibitor for treatment of schizophrenia and other mental disorders, encouraging further development of novel compounds of these mechanisms and lending further support to glutamate hypothesis of schizophreniaand other mental disorders.
Research Article: Transl Med (sunnyvale) 2014, 4: 127